Novo Nordisk

Novo Nordisk’s Logistics Win Offers a Lift, but the Washington Headache Is Just Beginning

Novo Nordisk’s Twin Clinical Wins Mask a Bruising Year and a Looming Medicare Showdown

angelina -

Novo Nordisk’s US Offensive and Buyback Battle a Steidous Share Price Slide

angelina -

Novo Nordisk Faces Shifting Competitive Landscape in Weight-Loss Drug Market

kashif hafeez -

Novo Nordisk’s Strategic Pivot: A High-Stakes Bet on Liver Disease

Brett Shapiro -

Novo Nordisk Forges Strategic Partnership Following Legal Dispute Resolution

angelina -

Novo Nordisk Takes Legal Action to Defend Key Obesity Drug

kashif hafeez -

Legal Action and Revised Forecasts Weigh on Novo Nordisk Shares

angelina -

Novo Nordisk’s Pivotal Year: Oral Drug Launch and Market Pressures Define 2026 Outlook

Brett Shapiro -

Novo Nordisk Shares Surge on Landmark Weight-Loss Pill Approval

Novo Nordisk Seeks FDA Approval for Next-Generation Weight Loss Therapy

angelina -

Novo Nordisk Shares Face Mounting Challenges Amid Competitive and Political Headwinds

Brett Shapiro -

Novo Nordisk Seeks Momentum with EMA Backing for Higher-Dose Obesity Drug

Novo Nordisk Shares Plunge as Weight-Loss Drug Dominance Fades

Novo Nordisk Faces Dual Challenges: Counterfeit Drugs and Patent Pressures

12Page 1 of 2